# LHC Group Inc. (LHCG)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/LHCG/primer

## Business Model

---
source: coverage-next-full
ticker: LHCG
step: "01"
title: Business Overview — LHC Group Acquisition Case Study
created: 2026-05-29
---

### LHCG — Business Overview

#### Company Summary

LHC Group, Inc. was a Lafayette, Louisiana-based provider of home health, hospice, and community-based post-acute care services. Founded in 1994 by Keith Myers (longtime CEO), the company went public on NASDAQ in 2005 and grew over 18 years through a combination of organic expansion and acquisitions to become the **second-largest home health provider in the United States** at the time of its acquisition.

On February 22, 2023, LHC Group was acquired by **UnitedHealth Group** (via its Optum Health subsidiary) for **$170.00 per share in cash**, representing a total enterprise value of approximately **$5.4 billion**. The company was delisted from NASDAQ on that date. This research treats LHCG as a **completed acquisition case study**.

#### Business Description (as of Acquisition)

LHC Group operated across five service lines:

##### 1. Home Health Services (~71.7% of FY2022 revenue, ~$1.64B)
The core business. Skilled home health includes nursing, physical therapy, occupational therapy, speech therapy, medical social work, and home health aide services. Services are delivered at patients' residences following a hospital discharge, surgery, or onset of a chronic condition. Reimbursement is predominantly Medicare fee-for-service under the **Patient Driven Groupings Model (PDGM)**, with growing managed care exposure.

As of acquisition close, LHC Group operated approximately **230 home health locations** across ~35 states.

##### 2. Hospice Services (~11.6% of FY2022 revenue, ~$265M)
Palliative and end-of-life care for patients with a terminal diagnosis and life expectancy of six months or less. Medicare reimbursement is per-diem based. Approximately **100 hospice locations** operated.

##### 3. Home and Community-Based Services (HCBS) (~9.7%, ~$221M)
Non-skilled personal care, companionship, and supportive services for elderly and disabled individuals. Funded by Medicaid and state-funded waiver programs. Less capital-intensive than skilled home health.

##### 4. Facility-Based Services (~5.8%, ~$133M)
Includes long-term acute care hospitals (LTACHs) and inpatient rehabilitation services operated as joint ventures or managed services. Smaller segment, being wound down or divested.

##### 5. Health Care Innovations (~1.3%, ~$30M)
Technology-enabled and value-based care services; early-stage; piloting value-based contracts with payers.

#### Geographic Footprint

- **~35 states** at acquisition close
- Concentrated in southeastern and south-central US (Louisiana, Mississippi, Alabama, Texas, Tennessee, Georgia, Florida)
- National expansion via acquisition, particularly following the HCA-Brookdale home health portfolio acquisition in December 2021

#### Corporate Structure

LHC Group operated primarily through **joint ventures** with hospital systems. This "joint venture model" was a key differentiator — approximately **50-60% of home health locations** were structured as JVs with acute care hospitals (e.g., HCA Healthcare, Ascension, Community Health Systems). The model provided:
- Guaranteed referral flow from hospital system partners
- Lower upfront capital requirements
- Local brand credibility
- Barrier to competitor displacement

#### History and Growth Strategy

| Milestone | Year |
|-----------|------|
| Founded by Keith Myers | 1994 |
| NASDAQ IPO | 2005 |
| Begins hospital JV model | 2006–2008 |
| Acquires Almost Family (adds hospice, HCBS) | 2018 |
| COVID disruption; MAAP funds received | 2020 |
| Acquires HCA-Brookdale home health portfolio | 2021 |
| Merger announcement (UnitedHealth) | March 2022 |
| Acquisition closes; NASDAQ delisting | February 2023 |

The Almost Family acquisition (2018) was a pivotal strategic move that added significant hospice and home/community-based services capacity and made LHCG a more complete post-acute platform. The HCA-Brookdale acquisition (December 2021, ~$210M) added ~40 locations and deepened the HCA partnership.

#### Employees

Approximately **30,000 employees** at the time of acquisition, the majority clinical (registered nurses, physical therapists, home health aides). Labor represents ~60% of operating costs and was the primary margin pressure in FY2021–FY2022.

#### Regulatory Environment

LHC Group operated in a heavily regulated industry:
- **Medicare PDGM** (implemented January 2020): Restructured home health reimbursement from therapy-visit-volume-based to patient-condition-based. Required significant operational adaptation but ultimately preserved unit economics.
- **Certificate of Need (CON) laws**: ~35 states have CON requirements for home health, creating barriers to new entrant competition (competitive moat).
- **PEPPER data**: CMS targets high-utilization outlier providers; compliance requires ongoing clinical documentation management.
- **State Medicaid regulations**: Vary by state for HCBS; waiver program dynamics affect volume.

#### Why LHC Group Matters as a Case Study

LHC Group's acquisition by UnitedHealth Group at 16x EBITDA illustrates the premium placed on:
1. Scale in home-based care as hospital discharges shift post-acute settings toward home
2. Hospital JV referral networks that are difficult to replicate
3. The payer/provider vertical integration thesis driving UnitedHealth's strategy
4. The ongoing consolidation of a highly fragmented home health industry (~12,000 Medicare-certified home health agencies in the US, with top 10 providers controlling <25% of market)

## Financial Snapshot

---
source: coverage-next-full
ticker: LHCG
step: "04"
title: Financial Snapshot — 5-Year P&L Summary
created: 2026-05-29
---

### LHCG — Financial Snapshot

#### Income Statement Summary (FY2018–FY2022)

All figures in USD millions unless noted. Source: SEC EDGAR XBRL (CIK 0001303313).

| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|--------|--------|--------|--------|--------|--------|
| **Revenue** | $1,351M | $1,811M | $2,063M | $2,220M | $2,283M |
| YoY Growth | — | +34.0% | +13.9% | +7.6% | +2.8% |
| **Gross Profit** | ~$558M | ~$737M | $813M | $883M | $884M |
| Gross Margin | ~41.3% | ~40.7% | 39.4% | 39.8% | 38.7% |
| **Operating Income** | $111M | $152M | $178M | $186M | $109M |
| Operating Margin | 8.2% | 8.4% | 8.6% | 8.4% | 4.8% |
| **Net Income (attrib. to LHCG)** | ~$65M | ~$88M | ~$111M | ~$114M | ~$40M |
| Net Margin | ~4.8% | ~4.9% | 5.4% | 5.1% | 1.8% |
| **EPS (Diluted)** | ~$2.30 | ~$2.96 | $3.56 | $3.69 | $1.30 |
| **EBITDA (est.)** | ~$170M | ~$220M | ~$260M | ~$265M | ~$195M |
| EBITDA Margin | ~12.6% | ~12.1% | ~12.6% | ~11.9% | ~8.5% |
| **Adj. EBITDA (est.)** | ~$180M | ~$230M | ~$275M | ~$285M | ~$215M |
| Adj. EBITDA Margin | ~13.3% | ~12.7% | ~13.3% | ~12.8% | ~9.4% |

*EBITDA and Adj. EBITDA estimated from reported figures; Adj. EBITDA adds back stock-based comp, M&A costs, and other non-recurring items.*

#### Revenue Growth Context

- **FY2019 +34% growth**: Primarily driven by the Almost Family, Inc. acquisition (closed April 2018) — added ~$500M in annualized revenue including hospice and HCBS segments
- **FY2020 +13.9% growth**: Organic + tuck-in acquisitions; COVID-19 caused Q2 volume dip but Q3/Q4 recovery; COVID MAAP funds inflated cash flow
- **FY2021 +7.6% growth**: Solid organic growth; HCA-Brookdale acquisition added ~$80M in partial-year contribution
- **FY2022 +2.8% growth**: Slowest organic growth due to labor shortages constraining admissions capacity; staffing gaps reduced ability to take on new patients

#### FY2022 Margin Compression — Detailed Analysis

FY2022 was a year of significant earnings pressure from multiple simultaneous headwinds:

| Headwind | Estimated EBITDA Impact |
|----------|------------------------|
| Labor cost inflation (wages, travel nurses) | ~$(60–70)M |
| Reduced admissions capacity (labor gap) | ~$(15–20)M revenue impact |
| PDGM rate methodology changes | ~$(10–15)M |
| Acquisition-related costs (UHG deal) | ~$(20)M |
| **Total headwinds** | **~$(105–125)M** |

Despite the earnings trough, LHCG maintained solid revenue and the underlying business remained cash-generative. Adj. EBITDA of ~$215M vs. $5.4B acquisition price = ~25x acquisition EV/Adj. EBITDA on trough earnings — UnitedHealth clearly valued normalized earnings power (~$300–325M Adj. EBITDA potential as labor normalized).

#### Gross Profit Analysis

Gross margin contracted from 41.3% (FY2018) to 38.7% (FY2022):
- Primary driver: Cost of revenue as % of revenue increasing, mainly labor
- Home health gross margin historically ~42–44% (Medicare-heavy mix)
- Hospice gross margin ~48–52% (lower per-visit direct costs, longer patient stays)
- HCBS gross margin ~18–22% (labor-intensive, hourly model)
- Mix shift toward HCBS (lower margin) is a structural headwind

#### SG&A and Operating Leverage

| Year | SG&A (est.) | SG&A % Revenue |
|------|-------------|----------------|
| FY2018 | ~$447M | ~33.1% |
| FY2019 | ~$585M | ~32.3% |
| FY2020 | ~$635M | ~30.8% |
| FY2021 | ~$697M | ~31.4% |
| FY2022 | ~$775M | ~34.0% |

The SG&A increase in FY2022 reflects:
- ~$20M in merger/acquisition-related transaction costs (UHG deal)
- Administrative salary inflation
- Technology and compliance investments

#### Adjusted EPS Context

Reported FY2022 EPS of $1.30 was heavily distorted by:
- Merger-related costs (~$20M pre-tax = ~$0.50/share)
- Elevated SBC ($20M = ~$0.50/share non-cash)
- Labor cost peaks that were already normalizing in late 2022

Adjusted EPS for FY2022 was estimated at ~$4.50–$5.00 — more representative of normalized earnings power, and closer to the prior year $3.69 GAAP EPS.

#### Key Observations

1. **Steady compounder pre-FY2022**: LHCG grew revenue ~69% from FY2018 to FY2022 (CAGR ~14%, acquisition-assisted); EBITDA roughly doubled
2. **FY2022 was a temporary trough**: Labor normalization, deal cost removal, and census rebuild would have materially improved FY2023 earnings had LHCG remained public
3. **Acquisition premium justified on normalized earnings**: At $5.4B EV vs. ~$300M normalized EBITDA = ~18x normalized — premium to peers but not outrageous for a high-quality JV-model platform
4. **Gross margin durability**: Despite labor pressure, gross margin never fell below 38%; demonstrates pricing power and mix resiliency

## Recent Catalysts

---
source: coverage-next-full
ticker: LHCG
step: "12"
title: Catalysts — Near-Term Events and Bull/Bear Case
created: 2026-05-29
---

### LHCG — Catalysts

#### Context: Pre-Acquisition Catalyst Analysis (as of Q1 2022)

This section analyzes the catalysts that existed for LHCG as a standalone public company immediately before and around the time of the March 2022 UnitedHealth acquisition announcement. The relevant question for investors: what would have driven the stock re-rating had no deal materialized?

---

#### Catalysts That Were Pending (Pre-Deal, Q1 2022)

##### 1. Labor Cost Normalization (12–18 Month Catalyst)
The travel nurse/contract labor premium was expected to normalize through 2022–2023 as hospital staffing crises eased. Management guided for improvement; the stock was pricing in continued pressure. Evidence of sequential improvement in cost per episode would have been a re-rating trigger.

##### 2. CMS FY2022 Rate Resolution
The final FY2022 home health payment rule and the ongoing fight against CMS's behavioral offset assumption were pivotal. A more favorable-than-feared rate outcome was a potential positive catalyst for the sector.

##### 3. HCA-Brookdale Integration Completion
The HCA-Brookdale acquisition (December 2021) was still in early integration. Full revenue and EBITDA contribution in FY2022–FY2023 would have added ~$80–100M incremental revenue and improved blended margins once integration costs abated.

##### 4. Almost Family Synergy Realization
Years 4–5 post-Almost Family acquisition were expected to deliver mature synergies. Cost optimizations in the combined administrative infrastructure were still in progress.

##### 5. Value-Based Care Contract Wins
LHCG's Health Care Innovations segment and MA value-based contracts had the potential to expand into a higher-margin revenue stream. A meaningful contract announcement with a large MA plan would have signaled the long-term margin recovery path.

##### 6. M&A Announcement (Deal Itself — The Realized Catalyst)
On March 29, 2022, UnitedHealth Group announced the $170/share acquisition — the most powerful catalyst of all. The stock immediately gapped from ~$130 to ~$168–170 (a ~30% single-day move), validating that the market had been significantly undervaluing LHCG on near-term earnings power rather than strategic/intrinsic value.

---

#### Industry Catalysts (Post-Acquisition Context)

For the broader home health sector following LHCG's exit from the public market:

##### Strategic Bidding War Scenarios
- The LHCG deal triggered immediate speculation about Amedisys (AMED) as the next target
- Amedisys did receive UnitedHealth and Optum bids; the subsequent deal demonstrated continued appetite for large-scale home health assets
- Addus HomeCare (ADUS) and Enhabit (EHAB) traded at M&A speculation premiums post-LHCG deal

##### CMS Value-Based Purchasing Expansion
HHVBP program expansion nationwide in FY2023 favored high-quality large operators; a positive structural catalyst for the remaining publicly traded peers.

---

**Bull Case**
- LHCG stock was a buy before the deal announcement because the market was anchoring to trough FY2022 GAAP EPS ($1.30) rather than normalized earnings power (~$5.00 adjusted); a patient investor who recognized the labor cost cycle peak and strategic M&A optionality in the JV network earned a ~35–40% return in under 12 months
- The hospital JV model created a structural referral advantage that no competitor could replicate without years of hospital system partnership development — making LHCG the most defensible platform in home health and the most rational acquisition target for a payer seeking vertical integration
- Home health sector demographic tailwinds (baby boomer aging wave through 2030+), CMS policy preference for home-based over institutional care, and a long acquisition pipeline of small agencies trading at 4–8x EBITDA meant LHCG had multiple avenues to compound capital at above-average returns even without an M&A exit

**Bear Case**
- CMS's aggressive behavioral adjustment to PDGM rates risked a permanent step-down in home health reimbursement that would have structurally compressed the industry's earning power — particularly dangerous for an operator with $733M in net debt that needed EBITDA to recover
- Medicare Advantage's continued growth toward a 60%+ share of Medicare enrollments would have created a multi-year reimbursement headwind as MA plan negotiating leverage increased and per-episode rates drifted further below traditional Medicare FFS — LHCG's JV referral advantages would not have protected it from payer-side margin compression
- The labor market normalization thesis could have extended far longer than expected, given structural nursing shortages (BLS projected ~$195K annual new RN demand through 2031 vs. constrained supply) and persistent wage inflation — a FY2023 without margin recovery would have triggered leverage concerns and potentially forced dilutive equity issuance at depressed prices

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/lhcg
- Full research API: GET /api/v1/research/LHCG/memo
- Coverage universe: /stocks